Stay updated on Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.

Latest updates to the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe webpage has been updated to reflect a new version of the study on Daratumumab and Dexamethasone for relapsed/refractory multiple myeloma, with changes in the principal investigator and collaborators. Key details about the study's purpose and methodology have been removed, which may impact the understanding of the study's scope.SummaryDifference42%
- Check21 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check79 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check86 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.